Cite
MLA Citation
A Dignass et al.. “A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL.” Journal of the Canadian Association of Gastroenterology, vol. 6, n.d., pp. 29–31. http://access.bl.uk/ark:/81055/vdc_100179861500.0x000003